Buscar
Mostrando ítems 1-10 de 148
Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
(Taylor and Francis Ltd, 2019)
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology
(Taylor and Francis Ltd, 2017)
GLP-1 and GLP-2 as Ying and Yang of Intestinal Lipoprotein Production: Evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin Resistant States
(American Diabetes Association, 2013-06)
The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 significantly reducing and ...
Circulating glucagon like peptide 1, (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance
(Universidad Autónoma Metropolitana. Unidad Lerma, 2014)
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
(BioMed Central, 2016)
BACKGROUND: The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or ...
Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats
(Elsevier B.V., 2015-04-01)
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that induces glucose-dependent stimulation of insulin secretion while suppressing glucagon secretion. Glucagon-like peptide-1 also increases beta cell mass and ...